Early identification of target candidates for pancreatic adenocarcinoma immunotherapy

Effective immunotherapy of pancreatic ductal adenocarcinoma (PDAC) is hampered by the lack of suitable tumor-specific antigens. To address this challenge, we have combined high-throughput flow cytometry with high-content cyclic immunofluorescence for the early identification of target candidates for cellular immunotherapy. Within this webinar, we aim to guide the viewers through our most recently published scientific findings[1] and related cutting-edge tools, ranging from the preparation of primary and xenografted tumor specimens to the comprehensive antigen screening and deep phenotyping. [1] Schäfer, D., Tomiuk, S., Küster, L.N. et al. Identification of CD318, TSPAN8 and CD66c as target candidates for CAR T cell based immunotherapy of pancreatic adenocarcinoma. Nat Commun 12, 1453 (2021).

 

 

Learning Objectives